Loading organizations...
§ Private Profile · Chicago, IL, USA
Prenosis develops data-driven diagnostic tools and precision medicine solutions for acute care conditions.
Prenosis is a biology-based technology company established in 2014, with its headquarters located in Chicago, Illinois. The company specializes in developing data-driven diagnostic tools and precision medicine solutions specifically for acute care environments. Its foundational belief is that healthcare should be tailored to individual biology, a principle it applies through innovative technological approaches.
Prenosis has raised $20.0M across 1 funding round.
Prenosis has received FDA De Novo marketing authorization for its Immunoscore product, an AI-powered diagnostic tool designed for sepsis.
Prenosis supports the integration of its technology into clinical workflows to help interpret complex patient data and provide predictive insights for acute care.
Prenosis has received FDA De Novo marketing authorization for its Immunoscore product, an AI-powered diagnostic tool designed for sepsis.
Prenosis supports the integration of its technology into clinical workflows to help interpret complex patient data and provide predictive insights for acute care.
Prenosis has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series A in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 29, 2026 | $20M Series A | PACE Healthcare Capital | Carle, Global Health Investment Corporation, Illinois Department OF Commerce & Economic Opportunity, LabCorp Venture Fund, UCI Health, UC Investments, UCI Health Ventures | Announced |
The company leverages artificial intelligence to interpret complex patient data, aiming to provide predictive insights that support clinical decision-making. This technology is designed to integrate seamlessly into existing clinical workflows, enhancing the ability of healthcare providers to manage acute conditions more effectively.
Prenosis's focus on acute care addresses the need for rapid and accurate diagnostics in critical situations. By combining advanced AI with biological understanding, the company seeks to improve patient outcomes through more personalized and timely interventions.
A significant achievement for Prenosis is the FDA De Novo marketing authorization of its Immunoscore product. This AI-powered diagnostic tool is specifically designed for sepsis, a life-threatening condition requiring prompt and precise diagnosis. The authorization underscores the company's commitment to bringing validated, data-driven solutions to market.
Through its continuous research and development, Prenosis aims to advance the field of precision medicine. The company's efforts are directed towards transforming how acute care conditions are diagnosed and managed, ultimately serving patients with more individualized and effective treatments.